Allosteric modulators of ligand binding to muscarinic acetylcholine receptors

Drug Discovery Today

Volumn 3, Issue 5, 1998, Pages 214-222

  Holzgrabe, Ulrike ^a   Mohr, Klaus ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,6 HEXAMETHYLENEBIS[DIMETHYL(3 PHTHALIMIDOPROPYL)AMMONIUM BROMIDE]; ACETYLCHOLINE; ALCURONIUM; ALLOSTERIC MODULATOR; GALLAMINE; HEXAMETHONIUM; METHOCTRAMINE; METHYLSCOPOLAMINE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OBIDOXIME; QUINIDINE; RECEPTOR PROTEIN; RECEPTOR SUBTYPE; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG; VERAPAMIL;

ALLOSTERISM; ANTINOCICEPTION; BINDING SITE; COGNITION; DISSOCIATION; DRUG SPECIFICITY; HUMAN; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0032076016     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(97)01161-6     Document Type: Review

References (71)

1. Bruns R.F., Fergus J.H. Mol. Pharmacol. 38:1990;939-949.
2. Nunnari J.M.et al. J. Biol. Chem. 262:1987;12387-12392.
3. Hoare S.R.J., Strange P.G. Biochem. Soc. Trans. 23:1995;92S.
4. Lee N.H., El-Fakahany E.E. Biochem. Pharmacol. 42:1991;199-205.
5. Tuček S., Proška J. Trends Pharmacol. Sci. 16:1995;205-212.
6. Lazareno S., Birdsall N.J.M. Mol. Pharmacol. 48:1995;362-378.
7. Kords H.et al. Eur. J. Pharmacol. 3:1968;341-346.
8. Lüllmann H.et al. Eur. J. Pharmacol. 6:1969;241-247.
9. Clark A.L., Mitchelson F. Br. J. Pharmacol. 58:1976;323-331.
10. Stockton J.M.et al. Mol. Pharmacol. 23:1983;551-557.
11. Jepsen K.et al. Pharmacol. Toxicol. 63:1988;163-168.
12. Tuček S.et al. Mol. Pharmacol. 38:1990;674-680.
13. Proška J., Tuček S. Mol. Pharmacol. 45:1994;709-717.
14. Kostenis E., Mohr K. Trends Pharmacol. Sci. 17:1996;280-283.
15. Ellis J., Seidenberg M. Mol. Pharmacol. 35:1988;173-176.
16. Ellis J., Huyler J., Brann M.R. Biochem. Pharmacol. 42:1991;1927-1932.
17. Tränkle C.et al. Mol. Pharmacol. 53:1998;304-312.
18. Kostenis E., Mohr K. Trends Pharmacol. Sci. 17:1996;443-444.
19. Ehlert F.J. Mol. Pharmacol. 33:1988;187-194.
20. Mohr K., Staschen C-M., Ziegenhagen M. Pharmacol. Toxicol. 70:1992;198-200.
21. Pfaffendorf M.et al. Life Sci. 60:1997;1172. abstract.
22. Franken C., Tränkle C., Mohr K. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;R24. abstract.
23. Leithäuser F., Mohr K., Staschen C-M. Pharmacol. Toxicol. 67:1990;317-321.
24. Ohnesorge F.K. Naunyn-Schmiedeberg's Arch. Pharmacol. 263:1969;72-88.
25. Tränkle C.et al. J. Pharmacol. Exp. Ther. 279:1996;926-933.
26. Jakubík J.et al. J. Pharmacol. Exp. Ther. 274:1995;1077-1083.
27. Hejnová L., Tuček S., El-Fakahany E.E. Eur. J. Pharmacol. 291:1995;427-430.
28. Burgmer, U. et al. Naunyn-Schmiedeberg's Arch. Pharmacol. (in press).
29. Waelbroeck M.et al. Life Sci. 60:1997;1174. abstract.
30. Kostenis E.et al. Eur. J. Pharmacol. 314:1996;385-393.
31. Maaß A., Kostenis E., Mohr K. Eur. J. Pharmacol. 272:1995;103-106.
32. Christopoulos A., Mitchelson F. Mol. Pharmacol. 46:1994;105-114.
33. Lanzafame A., Christopoulos A., Mitchelson F. J. Pharmacol. Exp. Ther. 282:1997;278-285.
34. Hilf G., Jakobs K.H. Eur. J. Pharmacol. 225:1992;245-252.
35. Jakubík J.et al. Proc. Natl. Acad. Sci. U. S. A. 93:1996;8705-8709.
36. Ellis J., Seidenberg M. Mol. Pharmacol. 42:1992;638-641.
37. Waelbroeck M. Mol. Pharmacol. 46:1994;685-693.
38. Proška J., Tuček S. Mol. Pharmacol. 48:1995;696-702.
39. Tränkle C., Mohr K. Mol. Pharmacol. 51:1997;674-682.
40. Ellis J., Seidenberg M., Brann M.R. Mol. Pharmacol. 44:1993;583-588.
41. Leppik R.A.et al. Mol. Pharmacol. 45:1994;983-990.
42. Matsui H., Lazareno S., Birdsall N.J.M. Mol. Pharmacol. 47:1995;88-98.
43. Ellis J. Drug Dev. Res. 40:1997;193-204.
44. Gerstin E.H. Jr., Luong T., Ehlert F.J. J. Pharmacol. Exp. Ther. 263:1992;910-917.
45. Wang S.Z.et al. Eur. J. Pharmacol. 296:1996;113-118.
46. Birdsall N.J.M.et al. Life Sci. 60:1997;1047-1052.
47. Growdon J.H. Life Sci. 60:1997;993-998.
48. Shannon H.E.et al. Life Sci. 60:1997;969-976.
49. Jakubík J.et al. Mol. Pharmacol. 52:1997;172-179.
50. Botero Cid H.M.et al. J. Med. Chem. 37:1994;1439-1445.
51. Kostenis E., Holzgrabe U., Mohr K. Eur. J. Med. Chem. 29:1994;947-953.
52. Tränkle C.et al. Life Sci. 60:1997;1995-2003.
53. Sadowski J., Gasteiger J. Chem. Rev. 93:1993;2567-2581.
54. Gasteiger J., Li X., Uschold A. J. Mol. Graphics. 12:1994;90-97.
55. Gasteiger J.et al. Pharmazie. 50:1995;99-105.
56. Holzgrabe U., Wagener M., Gasteiger J. J. Mol. Graph. 14:1996;185-193.
57. Holzgrabe U., Hopfinger A.J. J. Chem. Inf. Comput. Sci. 36:1996;1018-1024.
58. Burke, B.J. and Hopfinger, A.J. (1993) in 3-D QSAR in Drug Design - Theory Methods and Applications (Kubinyi, H., ed.), pp. 276-306, ESCOM Science.
59. Nassif-Makki T.et al. Eur. J. Pharm. Sci. 2:1994;138. abstract.
60. Gerry R.H.et al. Biochem. Pharmacol. 36:1987;2951-2956.
61. Mohr K., Tränkle C. Pharmacol. Toxicol. 35:1994;391-394.
62. Waelbroeck M.et al. Life Sci. 35:1984;1069-1076.
63. Proška J., Tuček S. Eur. J. Pharmacol. 305:1996;201-205.
64. Bejeuhr G.et al. Pharm. Pharmacol. Lett. 2:1992;100-103.
65. Bejeuhr G.et al. J. Pharm. Pharmacol. 46:1994;108-112.
66. Holzgrabe U.et al. Book Abstr. ACS. 213:1997;47.
67. Staudt M.et al. Life Sci. 62:1998;423-429.
68. Hoeltje H-D., Kier L.B. J. Pharm. Sci. 64:1975;418-420.
69. Dogherty D.A. Science. 271:1996;163-168.
70. Kerckhoff H., Hoeltje H-D. Pharmazie. 49:1994;566-573.
71. Jakubík J., Tuček S. Eur. J. Pharmacol. 289:1995;311-319.